In breast cancer cells, SRPK2 is modified with O-GlcNAc at its nuclear localization sequence, which enhances the binding of SRPK2 to importins, thus increasing nuclear translocation of SRPK2, independent of SRPK2 mTORC1/S6K1 phosphorylation (65). Here, SRPK2 is linked to breast cancer.